...We Welcome You To The Resverlogix HUB withIn The AGORACOM COMMUNITY!

Free
AGORACOM NEWS FLASH

Dear Agoracom Family,

I want to thank all of you for your patience with us over the past 48 hours and apologize for what was admittedly a botched launch of our new site.

As you can see, we have reverted back to the previous version of the site while we address multiple forum functionality flaws that inexplicably made their way into the launch.

To this end:

1.We have identified 8 fundamental but easily fixable flaws that will be corrected in the coming week, so that you can continue to use the forums exactly as you've been accustomed to.

2.Additionally we will also be implementing a couple of design improvements to "tighten up" the look and feel of the forums.

Sincerely,

George et al

Message: Last hour.....

Reata's Bardoxolone to treat a variety of rare kidney diseases is an activator of Nrf2. You know what else has recently been reported to be an activator of Nrf2 via increased transcription of Nrf2? The pan BET inhibitor JQ1. It would be extremely interesting if apabetalone (bromodomain-2 selective BET inhibitor) also increased the levels of Nrf2.

Bromodomain and Extraterminal (BET) Protein Inhibition Restores Redox Balance and Inhibits Myofibroblast Activation

BearDownAZ

Share
New Message
Please login to post a reply